PetVivo to exhibit at Fetch Kansas City veterinary conference

PetVivo Holdings will exhibit at the 2026 Fetch Kansas City Veterinary Conference in Kansas City, Missouri, from Aug. 28-30. The company plans to showcase its SPRYNG veterinary injectable as it works to build awareness and adoption among veterinary professionals.

Why it matters: - PetVivo is using a major veterinary conference to promote SPRYNG with OsteoCushion Technology to veterinarians who treat joint pain in cats, dogs and horses. - The event gives PetVivo a direct sales and awareness channel as the company looks to expand adoption of its flagship veterinary medical device.

What happened: - PetVivo Holdings said it will exhibit at the 2026 Fetch Kansas City Veterinary Conference in Kansas City, Missouri. - The conference runs Aug. 28-30, 2026, at the Kansas City Convention Center. - PetVivo said the exhibit will be at booth 916.

The details: - PetVivo plans to showcase SPRYNG with OsteoCushion Technology, an intra-articular injectable veterinary medical device made of sterilized extracellular matrix microparticles. - The microparticles are designed to adsorb onto the synovial lining of the joint and integrate with subsynovial tissue. - The intended result is support for proper joint mechanics and help managing noninfectious joint pain, including joint instability, degenerative joint disease and osteoarthritis. - Conference exhibit hours are listed as Friday, Aug. 28 from 10:15 a.m. to 6:30 p.m., Saturday, Aug. 29 from 10:15 a.m. to 4:45 p.m. and Sunday, Aug. 30 from 8:00 a.m. to 11:00 p.m. - PetVivo describes itself as an emerging biomedical device company focused on commercialization of innovative medical devices and therapeutics for equine and companion animals. - The company said SPRYNG with OsteoCushion Technology is currently available for commercial sale. - PetVivo said its portfolio includes 12 patents and six trade secrets protecting its biomaterials, products, production processes and methods of use.

Between the lines: - The company is pairing product marketing with professional outreach, which suggests PetVivo is still working to widen clinical awareness rather than relying only on existing demand. - CEO John Lai framed the conference as a place to share growing clinical experience with SPRYNG and discuss it as an additional option for osteoarthritis and other joint-related pain. - PetVivo also says its strategy is to move veterinary medical devices to market faster than more tightly regulated pharmaceuticals and biologics.

What's next: - PetVivo is likely to use the Fetch conference to meet practitioners, present product information and build relationships inside the veterinary community. - The company also directs interested parties to more information, PetVivo Animal Health and Spryng Health. - PetVivo provided contact information through info1@petvivo.com and CEO John Lai at (952) 405-6216.

The bottom line: - PetVivo is taking SPRYNG to a targeted veterinary audience as it tries to turn conference visibility into broader commercial adoption.